XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Note 12 - Segment Information
 3 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

The following tables set forth our segment information:

 

   

Three Months Ended June 30,

  
   

2023

    

2022

  

Revenues:

                

Sterilization and Disinfection Control

   $ 15,927     $ 14,774  

Clinical Genomics

     13,369       14,505  

Biopharmaceutical Development

     9,889       10,967  

Calibration Solutions

     11,460       10,207  

Total revenues (a)

   $ 50,645     $ 50,453  
                 

Gross profit:

                

Sterilization and Disinfection Control

   $ 11,591     $ 10,768  

Clinical Genomics

     6,728       7,849  

Biopharmaceutical Development

     6,433       7,077  

Calibration Solutions

     6,431       5,664  

Reportable segment gross profit

     31,183       31,358  

Corporate and Other (b)

     -       (17 )

Gross profit

   $ 31,183     $ 31,341  

Reconciling Items:

                

Operating expenses

     31,847       35,935  

Operating (loss)

     (664 )     (4,594 )

Nonoperating expense, net

     273       818  

(Loss) before income taxes

   $ (937 )   $ (5,412 )

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
 

(b)

 Unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

 

   

June 30,

    

March 31,

  
   

2023

    

2023

  

Sterilization and Disinfection Control

   $ 3,758     $ 3,492  

Clinical Genomics

     13,744       13,985  

Biopharmaceutical Development

     8,889       8,384  

Calibration Solutions

     9,168       8,781  

Total inventories

   $ 35,559     $ 34,642